GIST treatment decisions you can have confidence in
Oncology

GIST treatment decisions you can have confidence in

Gastrointestinal stromal tumors (GISTs) are the most common sarcoma of the GI tract (1). Globally, there are about 10–15 cases in every 1,000,000 people (2).

The therascreen PDGFRA RGQ PCR Kit is a CE-marked assay for the identification of patients with GISTs who may be eligible for treatment with AYVAKYT (avapritinib), based on a PDGFRA D842V mutation-detected result.

PDGFRA D842V mutations in GISTs

PDGFRA D842V mutations in GISTs

PDGFRA is the second most commonly mutated gene in GIST cases after the KIT gene. More specifically, an exon 18 D842V substitution is found in up to 75% of all PDGFRA-mutated tumors (3).

AYVAKYT (avapritinib), an approved TKI targeted at GISTs with the PDGFRA D842V mutation, has transformed cancer treatment for this subgroup of patients (4).

Reliably detect PDGFRA mutations

The therascreen PDGFRA RGQ PCR Kit is a real-time qualitative molecular assay for the detection of the D842V somatic mutation in the PDGFRA gene using genomic DNA extracted from formalin-fixed, paraffin-embedded (FFPE) tumor tissue from patients with GISTs.

Download flyer
Reliably detect PDGFRA mutations
Contact an expert
Discover how PDGFRA testing can help you and your patients.
Get in touch
Solid tumor webinar hub

The latest insights from oncology experts

Watch our most recent webinars on biomarker testing in solid tumors.

Visit hub

Enabling precision healthcare for your patients

Our therascreen kits for solid tumor diagnostics lets you access relevant genomic information for each patient and use it to make the best treatment decisions possible.

Browse our products
Enabling precision healthcare for your patients

 

The therascreen PDGFRA RGQ PCR Kit is intended for in vitro diagnostic use.

References

1. Soreide K, Sandvik OM, Soreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. Cancer Epidemiol. 2016;40:39-46.

2. Khan J, Ullah A, Waheed A, et al. Gastrointestinal stromal tumors (GIST): A population-based study using the SEER database, including management and recent advances in targeted therapy.  Cancers (Basel). 2022;14(15):3689.

3. Mei L, Smith SC, Faber AC, et al. Gastrointestinal stromal tumors: The GIST of precision medicine. Trends Cancer. 2018;4(1):74-91.

4. Bauer S, George S, von Mehren M, Heinrich MC. Early and next-generation KIT/PDGFRA kinase inhibitors and the future of treatment for advanced gastrointestinal stromal tumor. Frontiers in Oncology. 2021;11. doi:10.3389/fonc.2021.672500.